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Biallelic loss-of-function (LOF) mutations of the NCF4 gene, encoding the p40phox subunit of the phagocyte NADPH oxidase, 
have been described in only 1 patient. We report on 24 p40phox-deficient patients from 12 additional families in 8 countries. 
These patients display 8 different in-frame or out-of-frame mutations of NCF4 that are homozygous in 11 of the families 
and compound heterozygous in another. When overexpressed in NB4 neutrophil-like cells and EBV-transformed B cells 
in vitro, the mutant alleles were found to be LOF, with the exception of the p.R58C and c.120_134del alleles, which were 
hypomorphic. Particle-induced NADPH oxidase activity was severely impaired in the patients’ neutrophils, whereas PMA-
induced dihydrorhodamine-1,2,3 (DHR) oxidation, which is widely used as a diagnostic test for chronic granulomatous disease 
(CGD), was normal or mildly impaired in the patients. Moreover, the NADPH oxidase activity of EBV-transformed B cells was 
also severely impaired, whereas that of mononuclear phagocytes was normal. Finally, the killing of Candida albicans and 
Aspergillus fumigatus hyphae by neutrophils was conserved in these patients, unlike in patients with CGD. The patients suffer 
from hyperinflammation and peripheral infections, but they do not have any of the invasive bacterial or fungal infections seen 
in CGD. Inherited p40phox deficiency underlies a distinctive condition, resembling a mild, atypical form of CGD.
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to underlie variant CGD, in which residual activity does not dif-
fer between cell types (24). Hypomorphic CYBB mutations, which 
are more deleterious in monocyte-derived macrophages (MDMs) 
than in peripheral phagocytes, have been shown to underlie Men-
delian susceptibility to mycobacterial disease (MSMD) (25).
Much less is known about the fifth component, p40phox, as 
biallelic mutations of NCF4 have only been described once before 
in a young boy with severe colitis (26). p40phox has 3 domains: PX, 
PB1, and SH3 (27, 28). During phagocytosis, upregulation of the 
membrane phospholipid phosphatidylinositol 3-phosphate [PI(3)
P] and subsequent high-affinity binding of the p40phox PX domain 
enhance NADPH oxidase activity (21, 29). The p40phox-deficient 
patient is compound heterozygous for a premature stop codon 
and a missense mutation in the PX domain that compromises 
binding to PI(3)P, which results in the impairment of neutrophil 
phagocytosis–induced oxidase activity (26). As in classic CGD 
neutrophils, intracellular oxidant production after stimulation 
with serum-opsonized zymosan (SOZ), IgG beads, or serum- 
opsonized Staphylococcus aureus is impaired in the patient’s neu-
trophils, and S. aureus killing is also defective (20, 26, 30). How-
ever, in this patient, unlike in classic CGD patients, the produc-
tion of O2– by neutrophils in response to stimulation with PMA 
or formyl-methionyl-leucyl-phenylalanine (fMLF) is normal 
(26). The killing of S. aureus by neutrophils is also impaired in 
p40phox–deficient and CGD mice (31). However, p40phox-deficient 
murine neutrophils display highly impaired ROS production upon 
stimulation with PMA or heat-killed S. aureus, but not SOZ (32). 
Moreover, gp91phox- and p47phox-KO mice (33–35) seem to have a 
less severe form of inflammatory colitis than do p40phox-KO mice 
(36, 37). The cellular and clinical overlap and differences between 
human p40phox deficiency and classic CGD are largely unknown. 
Here, we describe the characteristics of 24 patients from 12 fami-
lies in 8 countries with biallelic mutations of NCF4.
Results
Biallelic NCF4 mutations in 24 individuals from 12 families in 8 coun-
tries. We studied 20 patients from 12 families with clinical features 
suggestive of CGD (kindreds A–L) (Tables 1 and 2 and Figure 1A). 
The families originated from Pakistan (kindreds A, B, E, and F), 
Portugal (kindreds C and J), Australia (kindred D), Colombia 
(kindred G), Argentina (kindred H), Kuwait (kindred I), Russia 
(kindred K), and Chile (kindred L). Whole-exome sequencing 
(WES) or targeted next-generation sequencing (NGS) with a panel 
of PID genes identified homozygous variants of the NCF4 gene 
in patients from 11 families: 2 variants affecting essential splice 
sites (c.118-1G>A in kindreds A, E, and K and c.32+2T>G in kin-
dred F); 3 missense variants (c.314G>A in kindred B, resulting in 
p.R105Q; c.172C>T in kindreds G and L, resulting in p.R58C; and 
c.430C>A in kindred H, resulting in p.P144T); 1 nonsense variant 
(c.716G>A in kindred I, resulting in p.W239X); and 1 in-frame 
deletion (c.120_134del in kindreds C and J). Finally, we detected 
compound heterozygous splice-site variants in 1 family (c.118-
1G>A and c.759-1G>C in kindred D). All variants were verified by 
Sanger sequencing. In 11 kindreds, the familial segregation of the 
alleles was consistent with an AR trait. Kindred J displayed unipa-
rental isodisomy (UPD), as both copies of chromosome 22 were 
inherited from the father (Figure 1A and ref. 38). Four asymptom-
Introduction
Chronic granulomatous disease (CGD) is a recessive primary 
immunodeficiency (PID) caused by loss-of-function (LOF) muta-
tions of autosomal or X-linked genes encoding 5 components of 
the phagocyte-reduced NADPH oxidase complex (1). This enzyme 
catalyzes the production of ROS in phagocytes. CGD was first 
described in 1954 (2), the first functional disorder of phagocytes 
was identified in 1966 (3), and the first genetic etiology of CGD, 
which is X-linked recessive (XR), was discovered in 1986 in the 
first positional identification of a PID gene (4, 5). The other genetic 
etiologies proved to be autosomal recessive (AR) (6). Patients with 
CGD suffer from recurrent, life-threatening, invasive infections 
with specific bacteria and fungi (7–10). Severe parasitic infections 
have rarely been reported in CGD patients, who also seem to have 
no particular predisposition to severe viral illnesses (11). Systemic 
hyperinflammation, including granulomatous lesions of the respi-
ratory and gastrointestinal (GI) tracts in particular, is also common 
(12–14). Patients with CGD may initially present with unexplained 
granulomatosis, which is associated with a poor prognosis, (13, 
15). Autoimmune conditions, such as systemic lupus erythemato-
sus, are rare in patients with CGD (16). The XR (gp91phox [phago-
cyte oxidase]) form of CGD is clinically more severe than the AR 
p47phox-deficient form (7, 9, 17). AR p22phox and p67phox deficiencies 
appear to be as severe as XR CGD (18, 19). Patients are routinely 
placed on prophylactic antimicrobial therapy, and the only cura-
tive treatment widely available is allogeneic hematopoietic stem 
cell transplantation (HSCT) (20).
The NADPH oxidase in human phagocytes is a complex of at 
least 5 subunits. The membrane-bound component is a hetero-
dimer consisting of gp91phox and p22phox, encoded by the X-linked 
CYBB gene and the autosomal CYBA gene, respectively. This 
heterodimer is known as flavocytochrome b558 and is the catalytic 
core of the NADPH oxidase complex (21). The second compo-
nent is a cytosolic heterotrimer composed of p40phox, p47phox, and 
p67phox, which form the regulatory part of the NADPH oxidase and 
are encoded by NCF4, NCF1, and NCF2, respectively (22). The 
membrane-bound and cytosolic components do not interact in 
steady-state conditions. Upon phagocyte activation, after the 
phagocytosis of a bacterium or fungus, for example, the 2 compo-
nents and a small GTPase (Rac1 and/or Rac2) are activated and 
assemble on the phagosomal membrane to produce superoxide 
(O2–) in the phagosome (23). This O2– is subsequently converted 
into hydrogen peroxide (H2O2) and other ROS, which together 
contribute to the destruction of the phagocytized microorganisms. 
LOF mutations of CYBB underlie the XR form of CGD, whereas 
LOF mutations of CYBA, NCF1, and NCF2 underlie the AR forms. 
Hypomorphic mutations of some of these genes have been shown 
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Figure 1. Identification of NCF4 
mutations. (A) Pedigrees of 12 families 
showing allele segregation. The index 
cases are indicated by an arrow, and 
“E?” indicates an unknown genotype. 
Black or white symbols represent 
individuals with or without clinical 
manifestations, respectively. Triangles 
represent pregnancies not carried 
to term. m, mutated. (B) Schematic 
diagram of the structure of the NCF4 
gene and p40phox protein, consisting 
of 9 exons and 3 protein domains, 
respectively. Newly discovered and 
previously reported mutations of the 
NCF4 gene are noted according to their 
localization. Red asterisks indicate 
mutations previously reported by 
Matute et al. (26).
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Figure 2. p40phox levels and 
NADPH oxidase activity of 
the NCF4-mutated alleles. (A) 
Western blot of total protein 
extracts from HEK293T cells 
expressing NCF4 cDNAs. The 
upper-panel data were obtained 
with a polyclonal anti-p40phox 
Ab, and the lower-panel data 
were obtained with an anti–DDK 
(Flag) Ab. An Ab against GAPDH 
was used as a loading control. 
(B) Western blot of total protein 
extracts from healthy control and 
NCF4–/– EBV–B cells retrovirally 
transduced with NCF4 cDNAs. A 
polyclonal anti-p40phox Ab was 
used, with an Ab against GAPDH 
as the loading control. NT, not 
transduced. (C) Production of O2– 
by NCF4–/– EBV–B cells retrovirally 
transduced with NCF4 cDNAs 
upon PMA stimulation. The 
results are representative of 2 
independent assays. LU, lumines-
cence units. (D) DHR reaction of 
NB4 p40phox-KO cells stimulated 
with PMA or (E) with E. coli. (F) 
Killing activity of NB4 p40phox-KO 
cells infected with S. aureus (n = 
2–3). Data represent the mean ± 
SEM (n ≥3) or the mean only (n 
<3) and were analyzed using a 
2-tailed Mann-Whitney U test. 
EV, empty vector.
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atic individuals were shown to carry biallelic mutations (kindreds 
E and G) (Figure 1A). None of the variants, other than p.R58C 
(minor allele frequency [MAF] = 0.001), was found in public data-
bases (Exome Aggregation Consortium [ExAC], Human Gene 
Mutation Database [HGMD], gnomAD, and Biomarker Recog-
nition and Validation Online [BRAVO]) or in our in-house WES 
database (~4,500 WES). Furthermore, combined annotation- 
dependent depletion (CADD) scores predicted all mutations to be 
deleterious, as these scores were above or close to the mutation 
significance cutoff (MSC) (ref. 24 and Supplemental Figure 1A; 
supplemental material available online with this article; https://
doi.org/10.1172/JCI97116DS1). The 3 missense mutations affect 
residues located in the PX domain of the p40phox protein (Figure 
1B). These residues are highly conserved in other species, sug-
gesting that they have an important function in the p40phox pro-
tein (Supplemental Figure 1B). We searched for a founder effect 
accounting for the presence of the c.120_134del, c.118-1G>A, and 
p.R58C mutations in different families. The patients homozygous 
for these mutations were genotyped with the genome-wide array 
6.0. The c.120_134del mutation in 2 Portuguese families (kindreds 
C and J) is within a common haplotype of 884 kb and 1,926 SNPs, 
demonstrating a founder effect. We dated the most recent com-
mon ancestor (MRCA) to 175 years ago (CI: 50–650 years). The 
c.118-1G>A variant in patients from Pakistan (kindreds A and E) is 
within a common haplotype of 337 kb and 136 SNPs. The MRCA 
of these kindreds was dated to 1,950 years ago (CI: 625–8,075 
years). The patient from Russia (kindred K) also shared a common 
haplotype of 152 kb and 41 SNPs in common with the 2 Pakistani 
patients, suggesting a common ancestor for these 3 patients, and 
the MRCA was estimated to have lived 6,275 years ago (CI: 2,475–
19,000 years) (39). Finally, the c.172C>T (p.R58C) mutation, pres-
ent in 2 Latin American kindreds, was within a common haplotype 
of 122 kb and 47 SNPs. The MRCA of these kindreds was dated to 
4,425 years ago (CI: 1,375–16,025 years). Collectively, these data 
suggest that 24 individuals from 12 kindreds in 8 countries suffer 
from inherited p40phox deficiency, including 20 symptomatic and 4 
asymptomatic individuals (Figure 1A).
Impaired NCF4 mRNA expression in the patients’ cells. We 
measured NCF4 transcript levels in cells from the patients and 
healthy controls by quantitative real-time RT-PCR (qPCR). EBV- 
transformed B cell lines (EBV–B cells) and neutrophils homozy-
gous for c.32+2T>G (patient 14 [P14]) produced no NCF4 tran-
scripts detectable by qPCR (Supplemental Figure 2A) or cDNA 
PCR (data not shown). These findings suggest that transcripts car-
rying this mutation are subjected to nonsense-mediated mRNA 
decay. For P12 (c.118-1G>A), P15 (p.R58C), P20 (p.W239X), and 
P22 (c.120_134del), we found that NCF4 transcript levels in EBV–B 
cells and neutrophils were lower than those in 10 unrelated con-
trols (Supplemental Figure 2A). Cells homozygous for c.118-1G>A 
or c.120_134del produced transcripts of lower molecular weight 
(MW), suggesting the occurrence of alternative splicing. Using 
TOPO-TA cloning, we detected 3 aberrantly spliced variants for 
c.118-1G>A, all of which were predicted to encode truncated pro-
teins, and we identified a fourth minor transcript (6%) with a large 
in-frame deletion, c.118_198del (Supplemental Figure 2B). For 
c.120_134del, most of the transcripts carried a 5-codon deletion 
(p.F41_V45del) at the beginning of exon 3, and another 3 aberrant-
ly spliced variants were predicted to encode truncated proteins 
(Supplemental Figure 2B). Finally, for the c.759-1G>C allele, we 
performed exon trapping. We obtained 3 spliced variants: 1 with 
the retention of 37 bp of intron 8a (63%), 1 in which all of intron 8a 
was retained (26%), and 1 with the retention of 16 bp of intron 8a 
(11%) (Supplemental Figure 2C).
The mutant NCF4 alleles are deleterious in EBV–B cells. We 
assessed the potential impact of all individual NCF4 alleles. We 
used HEK293T cells for analyses of p40phox protein expression, 
whereas, for analyses of p40phox function, we used EBV–B cells from 
P14 (homozygous for c.32+2T>G), designated NCF4–/–, as they 
produced no detectable NCF4 mRNA. We first evaluated protein 
expression by transfecting HEK293T cells with expression vectors 
carrying C terminally Flag-tagged WT or mutant NCF4 cDNAs 
(R58C, R105Q, P144T, W239X, c.118_198del, and c.120_134del). 
Immunoblot analyses revealed that the WT, R58C, R105Q, and 
P144T cDNAs encoded a single, full-length 40-kDa protein that 
was produced in large amounts. By contrast, cells transfected with 
the in-frame deletions c.118_198del and c.120_134del produced 
proteins with a lower MW, at much lower abundance. Finally, the 
protein encoded by W239X cDNA was not detected with an anti-
Flag Ab, whereas a truncated protein of approximately 25 kDa 
gave a low-intensity signal with an anti-p40phox Ab (Figure 2A). We 
investigated the mode of functioning of the mutant alleles (LOF 
or hypomorphic) in EBV–B cells, which express all components of 
the NADPH oxidase complex and produce ROS (25, 26, 40). We 
transduced NCF4–/– EBV–B cells from P14 with retroviruses for the 
overexpression of missense (R58C, R105Q, and P144T), in-frame 
deletion (c.120_134del), and nonsense (W239X) cDNAs. Western 
blotting confirmed that the missense proteins were expressed nor-
mally, whereas c.120_134del was produced in small amounts, and 
the W239X protein was undetectable (Figure 2B). We then eval-
uated ROS production in NCF4–/– EBV–B cells by measuring O2– 
levels after PMA stimulation. EBV–B cells transduced with the 
R58C, R105Q, P144T, c.118_198del, p.Asp254Serfs96*, and 
W239X alleles produced no detectable O2–. By contrast, retrotrans-
duction with the c.120_134del variant led to a small, reproducible 
increase in O2– production (Figure 2C). No H2O2 was generated 
following the retrovirus-mediated transduction of NCF4–/– EBV–B 
cells with any of the mutant alleles in these conditions (Supple-
mental Figure 3A). These data suggest that 6 of the 7 alleles tested 
were LOF, with the remaining allele (c.120_134del) being severely 
hypomorphic, at least under these experimental conditions.
The mutant NCF4 alleles are deleterious in NB4 cells. We then 
generated CRISPR-Cas9–KO p40phox NB4 cells, which we allowed 
to differentiate into neutrophil-like cells. NADPH oxidase activity 
and S. aureus killing capacity were assessed in p40phox WT cells, 
NB4-p40phox–KO cells, and in NB4-p40phox–KO cells reconstituted 
with alleles R105Q, R58C, c.120_134del, or c.118_198del or WT 
p40phox. We observed no decrease in PMA-induced extracellular 
H2O2 release or intracellular H2O2 generation in NB4-p40phox–
KO cells, as was the case with cells reconstituted with any of the 
mutant alleles, consistent with the results obtained with neutro-
phils from the previously reported p40phox-deficient patient (Fig-
ure 2D, Supplemental Figure 3B, and ref. 26). Assessments of 
extracellular H2O2 release in response to serum-opsonized E. coli 
and A. fumigatus hyphae showed that NADPH oxidase activity was 
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Figure 3. p40phox and NADPH oxidase subunit expression in p40phox-deficient cells. (A) Western blot of total protein extracts from the neutrophils of healthy 
controls, patients, and heterozygous relatives. Abs against p40phox protein were used. Actin or GAPDH protein was used as a loading control. (B) Western 
blot of total protein extracts from MDMs and MDDCs from a healthy control and p40phox-deficient patients. Detection was done with a polyclonal anti-p40phox 
Ab, and an Ab against GAPDH was used as a loading control. (C) Western blot of total extracts from EBV–B cells from a healthy control, p40phox-deficient 
patients, and XR and AR CGD patients. Abs against p40phox protein or gp91phox, p22phox, p67phox, and p47phox were used. Actin or GAPDH protein was used as a 
loading control. (D) Intracellular detection of gp91phox, p22phox, p67phox, and p47phox in EBV–B cells from a healthy control, p40phox-deficient patients, and XR and 
AR CGD patients. The results shown are representative of 2 independent assays. p40phox–/– indicates a patient reported in a previous study (26).
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oxidase activity to residual levels of activity, but always markedly 
higher than those in classic CGD cells (Figure 4A). We observed 
a similar pattern at several time points (Supplemental Figure 5A). 
The release of H2O2 and production of O2– were evaluated after 
stimulation with PMA, platelet-activating factor (PAF) plus fMLF, 
or SOZ. We found that H2O2 generation by the patients’ neutro-
phils was normal or subnormal, whereas neutrophils from patients 
with classic CGD produced no H2O2 or O2– (Supplemental Figure 
4C). Thus, neutrophils from p40phox-deficient patients had nor-
mal or impaired, but not abolished, ROS production as shown by 
extracellular detection tests, contrasting sharply with the results 
for neutrophils from patients with classic CGD.
Impaired NADPH oxidase activity in p40phox-deficient neutro-
phils exposed to particulate inducers. As previously reported in 
p40phox-KO mice, ROS production in neutrophils in response to 
particulate stimuli depends on the recruitment of p40phox protein 
to the endosomes (31). We therefore evaluated intracellular and 
extracellular ROS production by the patients’ neutrophils follow-
ing stimulation with serum-opsonized S. aureus, E. coli, A. fumig-
atus hyphae, or C. albicans. Particle-induced intracellular DHR 
oxidation after neutrophil stimulation with S. aureus or E. coli was 
severely impaired in all patients tested, as in neutrophils from 
patients with classic CGD (Figure 4B). By contrast, DHR oxidation 
in neutrophils stimulated with unopsonized or serum-opsonized 
C. albicans conidia was only partially impaired in the p40phox- 
deficient patients, whereas a more pronounced defect was 
observed in the neutrophils from patients with classic CGD (Fig-
ure 4C). Moreover, extracellular H2O2 release by the neutrophils 
of p40phox-deficient patients in response to S. aureus, E. coli, or 
A. fumigatus was only partially impaired (Supplemental Figure 
5D). Finally, oxygen consumption was slightly impaired in the 
cells of all p40phox-deficient patients tested after stimulation with 
either soluble (PMA) or particulate (E. coli, SOZ) stimuli (Sup-
plemental Figure 5E). We found that neutrophils lacking gp91phox 
had no activity at all. Heterozygous carriers of p40phox deficiency 
displayed no defects of ROS production (data not shown). These 
findings confirm that p40phox plays an essential role in the NADPH 
oxidase activity of neutrophils upon stimulation with bacteria and, 
to a lesser extent, fungi, suggesting the translocation of at p40phox 
to assist in activation of the NADPH oxidase complex in response 
to these microorganisms.
Normal NADPH oxidase activity in other myeloid cells from the 
patients. We demonstrated that p40phox expression in some patients 
was equally impaired in different types of phagocytes (Figure 3). 
We analyzed the effects on NADPH oxidase activity in these cells 
by evaluating ROS production in monocytes triggered by PMA- 
induced DHR oxidation. Monocytes from 6 patients (P12, P15, 
P16, P19, P20, and P22) responded similarly to cells from healthy 
controls (Supplemental Figure 5B). We further investigated 
the NADPH oxidase activity of MDMs, as previously described 
(25, 41). MDMs from healthy controls, P12, P20, and P22 had nor-
mal or low levels of H2O2 after stimulation, depending on the stim-
ulus, whereas MDMs from a patient with classic CGD released no 
H2O2 (Figure 5A). Finally, we assessed NADPH oxidase activity in 
MDDCs, again evaluating H2O2 release. We found that MDDCs 
from the 3 patients tested (P12, P20, and P22) released normal 
amounts of H2O2, as shown by comparison with MDDCs from 
impaired in NB4-p40phox–KO cells (Supplemental Figure 3B). This 
defect was restored by reconstitution with WT p40phox or the R58C 
allele, but not with the other 3 mutant alleles (Supplemental Figure 
3B). Nevertheless, for E. coli–induced intracellular DHR oxidation, 
only WT p40phox restored the NADPH oxidase activity (Figure 2E). 
Moreover, S. aureus killing was impaired in NB4-p40phox–KO cells 
as well as in cells reconstituted with the mutant alleles, except for 
the R58C allele (Figure 2F). These experiments suggest that the 
R105Q, c.120_134del, and c.118_198del alleles are LOF in terms of 
ROS production and S. aureus killing in NB4 cells. In contrast, the 
R58C allele is hypomorphic in the same experimental conditions. 
Collectively, these data indicate that all the NCF4 alleles tested 
are LOF, with the exception of c.120_134del in EBV–B cells and 
R58C in NB4 cells, at least upon overexpression.
Impaired p40phox expression in the patients’ phagocytes. We 
studied the expression of endogenous p40phox by Western blot-
ting in neutrophils, monocytes, MDMs, and monocyte-derived 
dendritic cells (MDDCs). We detected no p40phox protein in neu-
trophils from P1 (c.118-1G>A), P9 or P10 (c.120_134del), P11 
(c.118-1G>A/c.759-1G>C), P12 (c.118-1G>A), P14 (c.32+2T>G), 
P22 (c.120_134del), or P23 (c.118-1G>A). By contrast, neutro-
phils from P6 and P8 (R105Q) and from P15 and P16 (R58C) had 
normal levels of p40phox protein. Neutrophils from P20 (W239X) 
contained a lower-MW protein present at low abundance (Figure 
3A), which was consistent with the truncated protein observed 
upon W239X overexpression in HEK293T cells (Figure 2A). 
Western blotting also revealed that the levels of the other com-
ponents of the NADPH oxidase complex in the patients’ neutro-
phils were normal (Supplemental Figure 4). Finally, we detected 
no p40phox protein in MDMs or MDDCs from P12, P20, or P22, 
(Figure 3B). Thus, these mutations result in a loss of p40phox 
expression in various types of myeloid cells. Collectively, these 
data are consistent with those obtained for the overexpression of 
mutant cDNAs in recipient cells.
Impaired p40phox expression in the patients’ EBV–B cells. We per-
formed Western blotting to study the expression of the NADPH 
oxidase subunits in EBV–B cells (26). We observed a complete 
loss of expression of the p40phox protein in EBV–B cells from P12, 
P14, P20, and P22. By contrast, p40phox was detected, but at low 
abundance, in cells from P15 (Figure 3C). The other subunits of 
the NADPH oxidase complex, gp91phox, p22phox, and p47phox, were 
normally expressed in the cells of all patients, as shown by West-
ern blotting and flow cytometry with intracellular staining (Figure 
3, C and D) and by comparing with expression levels in gp91phox-, 
p22phox-, and p47phox-deficient patients. However, the expression 
of p67phox, which interacts with p40phox, was affected in the EBV–B 
cells (Figure 3D), but not the neutrophils (Supplemental Figure 
4). These findings indicate that p40phox is involved in stabilizing 
p67phox levels in EBV–B cells, but not in neutrophils.
Residual to normal levels of NADPH oxidase activity in 
p40phox-deficient neutrophils exposed to soluble inducers. We stud-
ied the impact of NCF4 mutations on NAPDH oxidase activi-
ty by evaluating ROS production in patients’ cells. The PMA- 
induced DHR test, which measures intracellular H2O2 generation, is 
widely used on neutrophils for the diagnosis of classic CGD (1). 
This test showed a wide range of intracellular ROS production 
activity in p40phox-deficient neutrophils, from completely normal 
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Figure 4. NADPH oxidase activity in p40phox- 
deficient neutrophils. (A) Intracellular ROS produc-
tion by DHR in neutrophils from healthy controls 
(n = 37), p40phox-deficient patients (n = 17), and 
CGD patients (n = 5) upon PMA stimulation (100 ng 
PMA/ml and 400 ng/μl). (B) Particle-induced DHR 
oxidation in neutrophils from healthy controls  
(n = 17 and n = 23), p40phox-deficient patients (n = 12 
and n = 14), and CGD patients (n = 3 and n = 6) upon 
stimulation with S. aureus (left) or E. coli (right). (C) 
DHR oxidation in neutrophils from healthy controls 
(n = 14 and n = 6), p40phox-deficient patients (n = 6  
and n = 5), and CGD patients (n = 4 and n = 3) upon 
addition of C. albicans, with (left) or without (right) 
opsonization. PMNs, polymorphonuclear neutro-
phils. Data represent the mean ± SEM.  
*P < 0.05, **P < 0.01, and ***P < 0.001, by 2-tailed 
Mann-Whitney U test.
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the patients and neutrophils from healthy controls (Supplemental 
Figure 7). Finally, we evaluated the formation of neutrophil extra-
cellular traps (NETs), a process for which ROS have been shown to 
be essential (46). We assessed NET formation in response to PMA 
in 3 patients from kindreds A, B, and C. Only neutrophils from kin-
dred B (expressing p40phox protein) produced NETs. We detected 
no NET production in the other p40phox-deficient families tested 
(without p40phox protein expression) or for gp91phox-deficient CGD 
neutrophils (Supplemental Figure 8). These findings suggest that 
NET formation is dependent on p40phox expression. Collectively, 
these data indicate that p40phox-deficient neutrophils have normal 
fungus-killing capacities, unlike classic CGD neutrophils.
Inflammatory lesions in patients with p40phox deficiency. Defi-
ciency of p40phox is not characterized by the invasive bacterial and 
fungal infections seen in patients with classic CGD, but mostly by 
inflammatory manifestations as well as autoimmunity and periph-
eral infections (Tables 1 and 2 and Figure 7A). We identified 20 
symptomatic patients, of whom 10 (50%) presented with skin 
inflammation (P1, P2, P3, P5, P6, P7, P8, P11, P19, and P24), with 
lupus-like cutaneous lesions (P1, P6, and P8) or discoid lupus (P3, 
P7, and P11). We found inflammatory, granulomatous GI manifes-
tations in 10 patients (50%), and these included oral ulcers (P1 
and P10), abscesses/granulomas (P1, P2, P3, P4, P5, P6, P7, P8, P9, 
P10, P11, P23, and P24), periodontitis (P9 and P21), gingivitis or 
gum inflammation (P9, P10, P20, P21), esophagitis (P21 and P23), 
gastritis (P20), Crohn-like inflammatory bowel disease (IBD) (P1, 
P11, P21, P22, P23, and P24), and perianal abscesses/fistula (P11, 
P20, P21, and P24). P24 suffered from chronic and severe IBD 
requiring immunosuppressive treatment and a total colectomy. 
Some lesions were probably both infectious and inflammatory, 
as is often seen in CGD. Three patients (15.7%) (P12, P14, and 
P19) reportedly suffered from pulmonary infections, including 
P12, who was later diagnosed with interstitial lung disease that 
responded well to systemic steroids rather than antibiotics, sug-
gesting an autoinflammatory component. Ab evaluations were 
performed in some patients (n = 7) suffering from exacerbated 
inflammation. P1, P4, P5, P7, P8, and P12 were negative for anti-
nuclear Abs (ANAs). By contrast, P14 was positive for ANAs and 
antineutrophil cytoplasmic Abs (ANCAs), suggesting autoimmune 
activity in this patient.
Peripheral but not invasive infections in patients with p40phox 
deficiency. We investigated the possible infectious causes of 
pulmonary manifestations in the cohort. No pathogen was iden-
tified in P19. Cutaneous infections were reported in 8 patients 
(42%) (P1, P4, P6, P7, P9, P11, P21, and P23), 3 of whom had at 
least 1 proven episode of S. aureus infection (P1, P11, and P23). 
One patient (P15) had two episodes of disseminated histoplas-
mosis, which was successfully treated with antifungal drugs and 
steroids. Ten patients from six different families were vaccinated 
against tuberculosis with live bacillus Calmette-Guérin (BCG) 
(Tables 1 and 2). No adverse effects were reported in 9 patients, 
whereas P19 developed local lymphadenitis (BCG-itis). This 
same patient subsequently suffered from meningitis caused by 
Mycobacterium avium. Interestingly, this patient was also hetero-
zygous for a dominant-negative LOF mutation of STAT1, which 
is responsible for MSMD (47). Four asymptomatic children, 
aged 1, 3, 8, and 10 years at diagnosis of p40phox deficiency, were 
healthy controls, and unlike MDDCs from classic CGD patients 
(Figure 5B). Overall, these data suggest that p40phox is redundant in 
monocytes, MDMs, and MDDCs in terms of the NAPDH oxidase 
activity triggered by PMA. Further experiments assessing particle- 
induced ROS production by monocytes, MDMs, and MDDCs are 
required to determine the extent of this redundancy.
Impaired NADPH oxidase activity in EBV–B cells from patients. 
We tested EBV–B cells from the p40phox-deficient patients studied 
here, patients with classic CGD, and the first reported patient with 
p40phox deficiency (42). In luminol bioluminescence assays, EBV–B 
cells from P12, P14, P15, and P20 displayed severely impaired 
NADPH oxidase activity (Figure 5C). By contrast, EBV–B cells 
from P22 (with c.120_134del) displayed residual luminescence, 
consistent with the results obtained following the retrovirus- 
mediated transduction of NCF4–/– EBV–B cells with the 
c.120_134del allele (Figure 2C). This allele is, therefore, also con-
stitutively hypomorphic. We then evaluated the release of H2O2 
in EBV–B cells from P12, P14, and P20. H2O2 detection was com-
pletely negative, as in cells from classic CGD patients. By contrast, 
EBV–B cells from P22 and P15 displayed a residual release of H2O2 
(Figure 5C). Finally, EBV–B cells from P12, P14, P15, and P20 were 
transduced with a p40phox WT cDNA. The rescue of p40phox protein 
expression was confirmed by immunoblotting before functional 
assays (Supplemental Figure 6A). Production of O2– in response 
to PMA stimulation was restored in the transduced EBV–B cells 
(Supplemental Figure 6B). These experiments with EBV–B cells 
demonstrate that p40phox is not redundant for NADPH oxidase 
complex activity in these cells. They also confirm that 1 of the 8 
NCF4 alleles is severely hypomorphic.
Impaired killing of Staphylococcus, but not of fungi, by the 
patients’ cells. We then assessed the ability of the patients’ neu-
trophils to kill various microorganisms that commonly cause dis-
ease in patients with classic CGD. We found that the phagocyto-
sis of serum-opsonized E. coli, S. aureus, C. albicans, and SOZ by 
the patients’ neutrophils was similar to that by neutrophils from 
healthy controls and patients with classic CGD (data not shown). 
Nonoxidative phagocyte killing involves the release of the proteo-
lytic content of granules into the phagosome or at the neutrophil 
plasma membrane. In the p40phox-deficient neutrophils tested, 
protease release from the azurophilic granules (elastase, cathep-
sin G) in the dye-quenched–BSA (DQ-BSA) assay did not differ 
from that of neutrophils from healthy controls (data not shown) 
or patients with classic CGD (43). We therefore analyzed the 
phagocyte-mediated killing of different species of bacteria and 
fungi. The killing of S. aureus by the patients’ neutrophils was mark-
edly impaired for all the patients tested, similar to that observed 
for the classic CGD neutrophils (Figure 6A and ref. 44). E. coli kill-
ing was unaffected in the patients’ neutrophils, as in those from 
patients with classic CGD (Figure 6B and ref. 45). By contrast, the 
killing of A. fumigatus was normal or subnormal, whereas neutro-
phils from patients with classic CGD were completely incapable of 
killing these hyphae (Figure 6C). C. albicans killing by the patients’ 
neutrophils was similar to that by the neutrophils of healthy control 
cells when C. albicans was opsonized, whereas neutrophils from 
patients with classic CGD were unable to kill this fungus (Figure 
6D). Moreover, we observed that inhibition of the germination and 
hyphenation of Candida conidia were similar for neutrophils from 
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eral infections, mostly of the skin and lungs, and inflammation, 
mostly of the GI tract (Tables 1 and 2).
Favorable clinical outcome of p40phox-deficient individuals. Inher-
ited p40phox deficiency differs from classic CGD in terms of cellular 
found to have homozygous NCF4 mutations (P13, P16, P17, and 
P18), demonstrating incomplete clinical penetrance of the dis-
ease, at least until adolescence. In summary, p40phox deficiency 
conferred a variable phenotype marked by noninvasive periph-
Figure 5. NADPH oxidase activity in p40phox-deficient 
mononuclear cells. (A) Extracellular H2O2 production by 
MDMs from healthy controls (n = 5), p40phox-deficient 
patients (n = 3), and CGD patients (n = 1) upon PMA stim-
ulation (with and without IFN-γ priming). (B) Extracellular 
H2O2 production by MDDCs from healthy controls (n = 5), 
p40phox-deficient patients (n = 3), and CGD patients (n = 1) 
upon PMA stimulation (with and without LPS priming). 
(C) Production of O2– (left) and release of H2O2 (right) by 
EBV–B cells from healthy controls (n = 2), p40phox-deficient 
patients (n = 6), and CGD patients (n = 1) upon PMA stim-
ulation, assessed on the basis of luminol bioluminescence 
or Amplex Red test. The results are representative of 2 
independent assays. Data represent the mean ± SEM. NS, 
no stimulation.
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are between the ages of 1 and 47 years (mean: 15.3 years), whereas a 
mortality of close to 4% per year has been reported for classic CGD 
(6, 17), with the highest mortality rates during the first 2 decades of 
life. The Kaplan-Meier curves for the survival of the largest classic 
CGD cohort and this p40phox-deficient cohort differed significant-
ly when comparing XR-CGD and p40phox deficiency (P = 0.0164, 
Mantel-Cox analysis) (Figure 7C and Supplemental Table 2). 
Fourteen patients were prescribed antibiotic prophylaxis. The 
phenotype and clinical manifestations, but also in terms of clinical 
outcome (Supplemental Table 1). The mean age at symptom onset 
was 6 years (range: 1–17 years), later than what was reported for 
symptom onset in most patients with classic CGD (Supplemental 
Table 2). The mean age at diagnosis (for patients with symptoms) 
was 15.3 years (range: 1–46 years), whereas classic CGD is typically 
diagnosed before the age of 5 years (Figure 7B and Supplemental 
Table 2). All patients included in this study are currently alive and 
Figure 6. Pathogen killing activity by neu-
trophils from p40phox-deficient patients. (A) 
S. aureus viability was measured in infected 
neutrophils from healthy controls (n = 22), 
p40phox-deficient patients (n = 13), and CGD 
patients (n = 3). (B) E. coli viability was measured 
in infected neutrophils from healthy controls 
(n = 20), p40phox-deficient patients (n = 10), and 
CGD patients (n = 4). (C) A. fumigatus hypha 
viability was measured at different time points 
with infected neutrophils from healthy controls 
(n = 13), p40phox-deficient patients (n = 13) and 
CGD patients (n = 3). (D) C. albicans conidial 
viability was measured with infected neutrophils 
from healthy controls (n = 15), p40phox-deficient 
patients (n = 12), and CGD patients (n = 6). Data 
represent the mean ± SEM (n ≥3) or the mean 
only (n <3). (A–C) **P < 0.01 and ***P < 0.001, 
by 2-tailed Mann-Whitney U test. (D) ***P < 
0.001, by 2-tailed Mann-Whitney U test, and P 
< 0.0063, by 2-tailed Mann-Whitney U test with 
Bonferroni’s correction for multiple comparisons.
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ciency of p40phox is caused by homozygous (23 patients, 11 fami-
lies) or compound heterozygous (1 patient) mutations in families 
from 8 countries. We identified 8 previously undescribed alleles 
of the NCF4 gene, 6 of which are completely LOF and caused 
complete p40phox deficiency in the corresponding patients. Upon 
overexpression, the allele c.120_134del is hypomorphic in EBV–B 
cells, and the allele R58C is hypomorphic in NB4 cells. However, 
we detected no clinical difference between the patient bearing 
these variants and the other patients. We further characterized 
phagocytic cells from the p40phox–deficient patients and com-
pared them with those of patients with other molecular causes of 
CGD to define more clearly the contribution of human p40phox to 
NADPH oxidase activity. Interestingly, NCF4 biallelic mutations 
treatments administered for hyperinflammation included corti-
costeroids, azathioprine, methotrexate, infliximab, adalimumab, 
golimumab, ustekinumab, and hydroxychloroquine. Given the 
severity of clinical manifestations, 4 patients underwent allogeneic 
HSCT (P11, P14, P20, and P21), resulting in the resolution of symp-
toms in all these patients. Overall, p40phox deficiency is a severe 
condition, but its clinical outcome is nevertheless better than that 
of classic CGD.
Discussion
We report the molecular, cellular, and clinical characteristics of 
24 patients from 12 families with biallelic mutations of the NCF4 
gene, which encodes the NADPH oxidase p40phox protein. Defi-
Figure 7. Clinical manifestation and outcome of p40phox-deficient patients. (A) P20 images show cheilitis, episcleritis, severe chronic cutaneous lesions, 
and esophagitis. P21 images show esophagitis. P12 images show multifocal consolidations and infiltrates in both the lungs on x-ray and thorax on CT 
scan. P22 images show vulvar lichen planus before (top) and after (bottom) steroid treatment. (B) Distribution of age at diagnosis of CGD in the American 
(ref. 7) and European (ref. 9) cohorts and of the p40phox-deficient patients in this study. (C) Kaplan-Meier survival curve compiling survival data on 363 CGD 
patients (n = 240 XR CGD and n = 123 AR CGD) from refs. 7 and 19 and on the p40phox-deficient patients studied here.
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the patients in our cohort (P20) had adenocarcinoma, possibly 
related to chronic Crohn’s colitis, although other factors may 
also be involved.
Other clinical features of the patients can be understood in 
light of their cellular phenotypes. In vitro S. aureus killing by neu-
trophils from patients with p40phox deficiency or classic CGD was 
severely impaired, whereas E. coli killing by neutrophils from these 
patients was similar to that by neutrophils from healthy controls. S. 
aureus killing is a ROS-dependent process, whereas E. coli killing 
is relatively ROS independent (45, 51). The absence of invasive S. 
aureus infections in the p40phox-deficient patients was unexpected 
and remains unexplained, as both in vitro S. aureus–induced oxi-
dase activity and S. aureus killing are as severely impaired in these 
patients as in those with classic CGD, who do suffer from invasive 
S. aureus infections. The almost normal killing of fungi by neu-
trophils from p40phox-deficient patients, even though the killing 
of Candida and Aspergillus is ROS dependent (52, 53), is of direct 
clinical relevance and contrasts with the situation in patients with 
classic CGD (54). The lack of invasive fungal infections is highly 
consistent with our in vitro biochemical findings for phagocytic 
cells from p40phox-deficient patients. Residual NADPH oxidase 
activity was generally higher in p40phox-deficient cells than in 
classic CGD cells, and in vitro fungal killing was largely unaffect-
ed. This situation contrasts with that for classic CGD, in which 
invasive fungal infections are among the most feared and life- 
threatening complications, despite antimicrobial prophylaxis (10), 
and for which fungus killing is impaired in vitro. Given the impor-
tance of p40phox-PX interactions with PI(3)P in the phagosome for 
the NADPH oxidase activity elicited by bacteria, the lack of effect 
on C. albicans–induced ROS production and killing is surprising. 
Normal fungal killing in these patients may also result from the 
residual fungus-induced NADPH oxidase activity observed, sug-
gesting a p40phox-independent mechanism for ROS production 
that is preferentially triggered by fungi. This implies that ROS pro-
duction would have to exceed a certain threshold for effective fun-
gal killing. Further studies of late phagosome formation in relation 
to p40phox localization and ROS formation might clarify the differ-
ences in S. aureus and C. albicans killing, which diverge in patients 
with p40phox deficiency, but not in those with classic CGD.
Interestingly, our studies of monocytes, MDMs, and MDDCs 
suggest that these cell types are not dependent on p40phox for 
PMA-induced NADPH oxidase activity. This situation contrasts 
with that for MSMD-causing gp91phox mutations, which disrupt 
NADPH oxidase activity in MDMs but not in other phagocytes 
(neutrophils, monocytes, and MDDCs) (25, 41). The conserva-
tion of NADPH oxidase activity may explain the milder infectious 
phenotype of p40phox-deficient patients than of patients with clas-
sic CGD, including the absence of invasive bacterial and fungal 
infections. This feature may be specific to human cells, as p40phox- 
mutant mouse macrophages (either KO or R58A mice) have 
impaired NADPH oxidase activity upon stimulation with a phys-
iological stimulus (36). The PX domain of p40phox is thought to 
have a high affinity for and specificity of binding to PI(3)P, a lipid 
on phagosomal membranes, leading to enhanced NADPH oxi-
dase activity. Further studies are required to evaluate NADPH 
oxidase activity in phagocytic cells other than neutrophils in 
patients with p40phox deficiency or classic CGD. In this respect, 
were found to result in a cellular phenotype related to but clearly 
different from that of other forms of CGD. In particular, the 
PMA-induced DHR oxidation test widely used for the diagnosis 
of CGD gave normal or just below normal values for patients with 
inherited p40phox deficiency. Diagnosis of p40phox deficiency can 
be achieved using serum-opsonized E. coli as a stimulus in routine 
DHR- or Amplex Red–based tests, which must be performed in a 
diagnostic laboratory with expertise in analysis of NADPH oxidase 
activity. A genetic approach based on Sanger sequencing or NGS 
of NCF4 might also facilitate the diagnosis of p40phox deficiency.
The clinical phenotype of patients with p40phox deficiency 
is also related to but different from that of patients with clas-
sic CGD. The patients in this cohort had peripheral infections 
(mostly staphylococcal) and hyperinflammation (mostly gran-
ulomatous lesions of the GI tract and skin). Nevertheless, the 
frequency of inflammatory lesions is lower than in patients with 
classic CGD (48). A few of the patients showed autoimmunity, 
but, strikingly, none had the invasive bacterial and fungal infec-
tions commonly seen in patients with classic CGD (7–9, 18). 
Consistent with these findings, the clinical outcome of p40phox 
deficiency is better than that of classic CGD. No deaths were 
recorded in this cohort of patients aged 1 to 46 years, whereas 
classic CGD–related mortality may reach 35% in its XR and 15% 
in its AR forms in the first 3 decades of life (10, 17). Moreover, 
4 patients remained asymptomatic at 1 to 10 years of age, and 
the age at clinical onset ranged from 1 to 17 years in patients with 
symptoms. The incomplete clinical penetrance observed at 1 to 
10 years of age also contrasts strongly with observations for clas-
sic CGD (7–9, 18). Thus, the healthy siblings of probands should 
be tested immunologically and genetically. Curative and pre-
ventive treatments for CGD are based on prolonged treatment 
with regimens of antibiotics, antifungal drugs, exogenous IFN-γ, 
and, increasingly, allogeneic HSCT. Decisions concerning allo-
geneic HSCT for patients with p40phox deficiency should be made 
on a case-by-case basis, given the milder overall phenotype and 
greater variability between patients. Likewise, the immediate 
initiation of antifungal prophylaxis may not be required, whereas 
treatment with immunosuppressive agents may be indicated.
One patient with disseminated histoplasmosis (P15) was 
included in this cohort. However, to our knowledge, no patient 
with CGD has ever been reported to suffer from this fungal dis-
ease. This situation is reminiscent of that of tuberculosis, which 
is actually much more common than initially thought in CGD 
patients living in areas of endemic disease (49). Its pathogen-
esis has been attributed to defects of NADPH oxidase activity 
in mononuclear phagocytes (25). The normal NADPH oxidase 
activity of the p40phox-deficient mononuclear phagocytes tested 
suggests that histoplasmosis may actually be due to the disrup-
tion of NADPH oxidase activity in tissue-resident macrophages 
and DCs, which were not tested in patients with classic CGD or 
p40phox deficiency (50). Another patient in this cohort (P19) had 
BCG and M. avium diseases. BCG disease has been reported 
in CGD patients, but cases of M. avium complex infection have 
rarely been reported in this population. Moreover, these 2 myco-
bacterial infections are probably not related to p40phox deficien-
cy in P19, because this patient also carries a dominant-nega-
tive STAT1 mutation responsible for MSMD (47). Finally, 1 of 
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Scientific). Cells were stimulated with PMA (100 ng/ml), PAF (1 μM) 
followed by fMLF (1 μM) (all from Sigma-Aldrich), E. coli (OD600 0.1, 
strain ML-35 in the presence of 2 mM azide), and S. aureus (OD600 0.1, 
strain Oxford in the presence of 2 mM azide) or A. fumigatus hyphae 
(clinical isolate). We used 0.25 × 106 cells/ml, and the experiments 
were performed as previously described (65). The same method was 
used for the MDMs, MDDCs, and EBV–B cells, except that 400 ng/ml 
PMA was also added to the cells. The above-mentioned reagents and 
E. coli, S. aureus, and A. fumigatus strains were used in all experiments. 
Particles were opsonized with 10% (v/v) pooled human serum. MDMs 
and MDDCs were obtained by differentiation as previously described 
(25, 41). MDMs were cultured for 16 to 18 hours with 1 mg/ml puri-
fied protein derivatives (PPDs) (tuberculin PPD Batch RT49, Statens 
Serum Institute) or 5 × 103 IFN-γ IU/ml (Imukin, Boehringer Ingel-
heim) and then washed and activated by incubation for 30 minutes 
with PMA, or left unactivated. MDDCs were treated with LPS (1 μg/
ml Salmonella minnesota, Sigma-Aldrich), alone or immediately before 
treatment with PMA.
The production of intracellular ROS by neutrophils, monocytes, 
and NB4 cells was analyzed with DHR (Thermo Fisher Scientif-
ic), as previously described (66). We added 0.5 μM DHR in DMSO 
to 2.5 × 106 neutrophils. PMA (100 ng/ml), serum-opsonized E. coli 
or S. aureus (OD600 0.1 in the presence of 2 mM azide), C. albicans 
(OD625 0.1, strain SC5314), or SOZ (0.1 mg/ml) was then added. At 
the desired time points, samples were added to STOP buffer (0.5% 
[w/v] PFA, 1% [w/v] BSA, and 20 mM NaF in PBS), and the amount 
of rhodamine-1,2,3 (mean MFI [mean fluorescence intensity]) was 
assessed by flow cytometry using a FACSCanto II/LSR (BD Bioscienc-
es) and expressed as the percentage of rhodamine-1,2,3 produced by 
healthy control cells.
ROS production by monocytes was analyzed by assessing DHR 
after stimulation with PMA (400 ng/ml) in kindreds E, F, G, H, and J, 
using a Galios FACS Analyzer (Beckman Coulter) and an LSR Fortessa 
Cell Analyzer (BD). DHR is expressed as a percentage of the control, 
and MFI values were normalized against the healthy control.
Generation of NB4 p40phox-KO cells. The Optimized CRISP Design 
Tool (http://crispr.mit.edu/) was used (Zhang laboratory) to deter-
mine the Cas9 target sites present in the coding sequence of p40phox. 
An oligomer was cloned into the BsmBI site of pLentiCRISPR v2. The 
constructs were grown in E. coli Stbl3. Lentiviral particles were gen-
erated by the transient cotransfection of HEK293T cells with pLenti-
CRISPRv2, p40phox-KO, psPAX2, and pCMV-VSVg using TransIT-LT1 
Transfection Reagent (Mirusbio). The day after transfection, the cells 
were plated on NB4 medium. The virus-containing supernatant was 
harvested on days 2 and 3 after transfection and filtered through 0.45-
μm pores, and 1 ml was used with 5 × 105 NB4 cells on 2 successive 
days. Transduced NB4 cells were selected with 1 μg/ml puromycin 
(InvivoGen). Surviving cells were plated on limiting dilution medium 
in a 96-well plate at a density of 0.5 cells/150 μl, and growing clones 
were routinely maintained. The p40phox levels of these clones were 
assessed by Western blotting. A clone with no p40phox expression 
was obtained when the 5′-GTCAGCAATGTTGGCCGAGA-3′ target 
sequence was used.
Statistics. Statistical analysis was performed with GraphPad 
Prism, version 7.02 (GraphPad Software). All data sets were considered 
non-normally distributed, as the numbers were too low for normality 
tests. A 2-tailed Mann Whitney U test was used for statistical analy-
approaches involving the derivation of different types of phago-
cytes from induced pluripotent stem cells may be particularly 
effective (55).
Excessive granulomatous inflammation of the skin and GI 
tract was the most common clinical phenotype observed in this 
cohort of patients. Systemic lupus–like symptoms are rare in 
patients with CGD (7, 12, 20) and in the p40phox-deficient patients 
reported here. Enhanced inflammation has also been reported in 
mice with p40phox deficiency (36, 37, 56). Mouse p40phox has been 
reported to be required for the expression of glycan structure–
modifying enzymes, which may underlie the recruitment of neu-
trophils to resolve intestinal inflammation and facilitate wound 
healing (37). Mouse macrophages with p40phox p.R58A/R58A or 
KO mutations also produce smaller than normal amounts of ROS 
(36). The excessive inflammation seen in classic CGD and p40phox 
deficiency indicates that ROS play a role in immune regulation 
(12, 57). Patients with p40phox deficiency display at least as much 
inflammation as those with classic CGD, but have higher levels 
of ROS production. The ROS produced by neutrophils may con-
tribute to the clearance of apoptotic cells or cell debris, and their 
deficiency may contribute to inflammation in various ways, 
including aberrant efferocytosis, for example (58–62). Alterna-
tively, the inflammation observed in classic CGD and p40phox 
deficiency may be due to abnormal ROS production by circulating 
B cells. This possibility was already suggested in the first report 
describing a p40phox-deficient patient (42). Our results also suggest 
that NADPH activity is defective in all p40phox-deficient EBV–B 
cells tested, confirming that p40phox is not redundant in human B 
cells. An understanding of the excessive inflammation in patients 
with classic CGD or p40phox deficiency will require further stud-
ies of the respiratory burst in various other cell types, including 
tissue-resident DCs and macrophages, and in different types of 
circulating B cells.
Methods
Cell lines. NB4 cells were obtained from DSMZ (catalog ACC 207). 
HEK293T cells were obtained from the American Tissue Culture Col-
lection (ATCC) (catalog CRL-3216).
Ion torrent sequencing, WES, copy number variation, and Sanger sequenc-
ing. We extracted genomic DNA from blood samples with the iPrep Pure-
Link gDNA Blood Kit and iPrep Instruments (Life Technologies, Thermo 
Fisher Scientific). An AmpliSeq Custom Panel (Thermo Fisher Scientific) 
was used in families A–E, J, and K. A targeted NGS panel for PID was used 
in kindred I (63) and another for IBD was used in kindred J (64).
WES was performed with 3 μg DNA from kindreds F, G, H, and L. 
Exome capture was performed with the SureSelect Human All Exon 
72 Mb Kit (Agilent Technologies). SNP arrays for CNV or ancestral 
founder effect were used with the Genome-Wide Human SNP Array 
6.0 (Affymetrix) in kindreds A, C, E, G, J, K, and L.
For confirmation of the mutations detected and the analysis of 
familial segregation for kindred members, we amplified the flanking 
regions of the variants obtained, including part of the intronic regions 
for all NCF4 exons studied. Primers and conditions are described in 
detail in Supplemental Table 3.
NADPH oxidase functional assays. NADPH oxidase activity on neu-
trophils and NB4 cells was assessed by measuring extracellular H2O2 
release with an Amplex Red Kit (Life Technologies, Thermo Fisher 
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